专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明公开

EP2429575A1 COMPOSITIONS AND METHODS FOR IMMUNODOMINANT ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS 审中-公开
标题翻译： ZUSAMMENSETZUNGEN UND VERFAHRENFÜRIMMUNDOMINANTE ANTIGENE VON MYCOBACTERIUM TUBERCULOSIS
公开(公告)号：EP2429575A1
公开(公告)日：2012-03-21
申请号：EP09789675.7
申请日：2009-05-13
申请人： Immport Therapeutics, INC. , Liang, Xiaowu
发明人： FELGNER, Philip , GENNARO, Maria Laura
IPC分类号： A61K39/04 , C12Q1/68
CPC分类号： A61K39/04 , C12Q1/689 , G01N33/5695
摘要： Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.
摘要翻译：研究的组合物，装置和方法被描绘为来自病原体结核分枝杆菌的各种抗原及其在疫苗，治疗剂和各种诊断测试中的用途。在特别优选的方面，抗原是免疫显性的，并且相对于感染病原体的群体的血清具有定量和已知的相对反应性，和/或已知与疾病参数的关联。

52. 发明公开

EP2426141A2 Method for preventing or treating M tuberculosis infection 有权
标题翻译：维尔法赫恩zur Vorbeugung oder Behandlung einer M-tuberculosis-Infektion
公开(公告)号：EP2426141A2
公开(公告)日：2012-03-07
申请号：EP11190079.1
申请日：2006-04-27
申请人： GlaxoSmithKline Biologicals S.A. , INFECTIOUS DISEASE RESEARCH INSTITUTE (IDRI)
发明人： Marchand, Martine
IPC分类号： C07K14/35 , A61K39/04
CPC分类号： A61K39/04 , A61K31/4409 , A61K31/496 , A61K2039/523 , A61K2039/53 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/575 , C07K14/35
摘要： The present invention provides polypeptides, polynucleotides comprising a nucleic acid sequence encoding said polypeptides and related pharmaceutical compositions.
摘要翻译：本发明提供了多肽，包含编码所述多肽的核酸序列和相关药物组合物的多核苷酸。

53. 发明公开

EP2302033A3 Identification of virulence associated regions RD1 and RD5 enabling the development of improved vaccines of M. bovis BCG and M. microti 审中-公开
标题翻译：毒力相关联的区域RD1和RD5的鉴定使得能够提高疫苗的牛分枝杆菌BCG和田鼠分枝杆菌的发展
公开(公告)号：EP2302033A3
公开(公告)日：2012-03-07
申请号：EP10179423.8
申请日：2003-04-01
申请人： Institut Pasteur
发明人： Cole, Stewart , Pym, Alexander S , Brosch, Roland , Brodin, Priscille , Majlessi, Laleh , Leclerc, Claude , Demangel, Caroline
IPC分类号： C12N1/36 , A61K39/04 , G01N33/569 , C12N15/11 , C07K14/35
CPC分类号： A61K39/04 , A61K39/00 , A61K2039/522 , A61K2039/523 , C07K14/35 , C12N1/36 , C12Q1/689 , G01N33/5695
摘要： The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M. bovis BCG::RD1 or M. microti ::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.

54. 发明公开

EP2421557A1 A TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATION 有权转让
标题翻译：结核病结核病疫苗，以防止重新激活
公开(公告)号：EP2421557A1
公开(公告)日：2012-02-29
申请号：EP10766664.6
申请日：2010-04-23
申请人： Statens Serum Institut
发明人： DIETRICH, Jes , ANDERSEN, Peter , LUNDBERG, Carina, Vingsbo , HOANG, Truc, Thi, Kim, Than
IPC分类号： A61K39/04 , A61P11/00 , C07K14/35 , C07K19/00
CPC分类号： C07K14/35 , A61K39/04 , A61K2039/545
摘要： The present invention discloses a vaccine or immunogenic composition that can be administred to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (
Mycobacterium tuberculosis., M.bovis, M.africanum ), The invention is base on a number of
M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.

55. 发明授权

EP1877426B1 METHOD FOR PREVENTING OR TREATING M TUBERCULOSIS INFECTION 无效
标题翻译： VERFAHREN ZUR VORBEUGUNG ODER BEHANDLUNG EINER M.-TUBERCULOSIS-INFEKTION
公开(公告)号：EP1877426B1
公开(公告)日：2012-02-01
申请号：EP06753523.7
申请日：2006-04-27
申请人： GlaxoSmithKline Biologicals SA , INFECTIOUS DISEASE RESEARCH INSTITUTE (IDRI)
发明人： COLER, Rhea , LOBET, Yves , REED, Steven
IPC分类号： C07K14/35 , A61K39/04
CPC分类号： A61K39/04 , A61K31/4409 , A61K31/496 , A61K2039/523 , A61K2039/53 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/575 , C07K14/35
摘要： The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
摘要翻译：本发明提供了多肽，包含编码所述多肽的核酸序列和相关药物组合物的多核苷酸。

56. 发明公开

EP2402023A1 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails 审中-公开
标题翻译：通过用作为蛋白质片段或肽混合物递送的抗原接种来扩大t细胞库以包括亚优势表位
公开(公告)号：EP2402023A1
公开(公告)日：2012-01-04
申请号：EP11182884.4
申请日：2007-06-26
申请人： Statens Serum Institut
发明人： Aagaard, Claus , Dietrich, Jes , Andersen, Peter
IPC分类号： A61K39/04 , A61K39/02 , A61K39/12 , A61K39/002
CPC分类号： A61K39/00 , A61K39/04 , A61K2039/55511 , A61K2039/5555 , Y02A50/412
摘要： The present invention teaches a way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease by immunizing with pools of overlapping fragments (synthetic peptides e.g. 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The resulting T-cell response to subdominant epitopes is important for protection against chronic diseases that on their own induces a response focused only towards immunodominant epitopes. The present invention requires no prior knowledge of the precise localisation and identity of the subdominant epitopes and their recognition in a human population, but expands the T-cell repertoire and thereby the total number of epitopes recognized by specific T cells primed by vaccination from a few immunodominant epitopes to multiple of epitopes of vaccine relevance. For chronic disease controlled by humoral immunity the T helper cell response primed by the peptide mix may be boosted by the full size protein for maximum induction of an antibody response as well.
摘要翻译：本发明教导了一种通过用重叠片段库（合成肽例如10-30个菌体，用2-氨基吡啶）免疫来诱导广泛识别对任何给定抗原的表位具有显性和次优势反应的重要性的方法，所述重要性用于预防或治疗慢性疾病。 20个氨基酸重叠）在合适的佐剂中所需的抗原。当完整分子用于免疫接种并由慢性感染自身诱导时，T细胞库不仅包括识别的免疫优势表位，而且还诱导对许多亚优势表位的更广泛和平衡的应答。产生的对亚优势表位的T细胞反应对于防止慢性疾病的保护是重要的，所述慢性疾病本身诱导仅针对免疫显性表位的应答。本发明不需要预先知道亚群表位的精确定位和同一性以及它们在人类群体中的识别，但是扩增了T细胞库，并由此扩大了由接种疫苗引发的特定T细胞识别的表位的总数免疫显性表位与疫苗相关性的多个表位相关联。对于由体液免疫控制的慢性疾病，由肽混合物引发的T辅助细胞应答可以被全长蛋白质加强以最大程度地诱导抗体应答。

57. 发明公开

EP2389433A2 MYCOPLASMA GALLISEPTICUM FORMULATION 有权
标题翻译：鸡毒支原体配方
公开(公告)号：EP2389433A2
公开(公告)日：2011-11-30
申请号：EP10733876.6
申请日：2010-01-22
申请人： University Of Georgia Research Foundation, Inc.
发明人： KLEVEN, Stanley, H. , FERGUSON, Naola, M.
IPC分类号： C12N1/20 , A61K39/04 , C12R1/32
CPC分类号： A61K39/0241 , A61K39/12 , A61K2039/522 , A61K2039/552 , C12N2760/18134 , C12R1/35
摘要： The present invention provides a formulation that prevents virulent Mycoplasma galHsepticum infection in birds of the order GaIHf ormes. The formulation comprises live Mycoplasma galHsepticum strain K5831 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma galHsepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

58. 发明授权

EP1914299B1 Identification of virulence associated region RD1 enabling the development of improved vaccines of M. microti 有权
标题翻译：毒力相关区域RD1，这使得能够改善Impstoffen的发展与田鼠分枝杆菌的鉴定
公开(公告)号：EP1914299B1
公开(公告)日：2011-11-30
申请号：EP07122295.4
申请日：2002-04-05
申请人： INSTITUT PASTEUR
发明人： Cole, Stewart , Pym, Alexander S , Brosch, Roland , Brodin, Priscille , Majlessi, Laleh , Leclerc, Claude
IPC分类号： C12N1/36 , A61K39/04 , G01N33/569 , C12N15/11 , C07K14/35
CPC分类号： A61K39/04 , A61K39/00 , A61K2039/522 , A61K2039/523 , C07K14/35 , C12N1/36 , C12Q1/689 , G01N33/5695

59. 发明公开

EP2380590A2 Improved tuberculosis vaccines 审中-公开
标题翻译： Verbesserte Tuberkuloseimpfstoffe
公开(公告)号：EP2380590A2
公开(公告)日：2011-10-26
申请号：EP11171153.7
申请日：2006-06-20
申请人： Statens Serum Institut
发明人： Vingsbo-Lundberg, Carina , Aagaard, Claus , Andersen, Peter
IPC分类号： A61K39/04 , C07K14/35 , A61P31/06
CPC分类号： C07K19/00 , A61K39/00 , A61K39/04 , C07K14/35 , C07K2319/00
摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( M. tuberculosis , M. bovis , M. africanum , M. microti ). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
摘要翻译：本发明涉及用于预防，增强或治疗由结核分枝杆菌菌种（M.tuberculosis，M.Bovis，M. africanum，M.Microti）引起的感染的免疫原性组合物，疫苗或药物组合物。免疫原性组合物，疫苗或药物组合物包含融合多肽，其包含来自结核分枝杆菌的一种或多种饥饿抗原，融合多肽的单位是结核分枝杆菌抗原。此外，本发明涉及包含与BCG同时给予的融合多肽序列或本发明的核酸序列的疫苗或与BCG混合或分别在不同部位或途径施用以制备所述免疫原性组合物的疫苗的用途，疫苗或药物组合物。

60. 发明公开

EP2380589A2 Improved tuberculosis vaccines 审中-公开
标题翻译：改进的结核病疫苗
公开(公告)号：EP2380589A2
公开(公告)日：2011-10-26
申请号：EP11171143.8
申请日：2006-06-20
申请人： Statens Serum Institut
发明人： Vingsbo-Lundberg, Carina , Aagaard, Claus , Andersen, Peter
IPC分类号： A61K39/04 , C07K14/35 , A61P31/06
CPC分类号： C07K19/00 , A61K39/00 , A61K39/04 , C07K14/35 , C07K2319/00
摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex ( M. tuberculosis, M. bovis, M. africanum, M. microti ) . The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
摘要翻译：本发明涉及用于预防，加强或治疗由结核复合物（结核分枝杆菌，牛分枝杆菌，非洲分枝杆菌，微小分枝杆菌）引起的感染的免疫原性组合物，疫苗或药物组合物。免疫原性组合物，疫苗或药物组合物包含融合多肽，其包含来自结核分枝杆菌的一种或多种饥饿抗原，融合多肽的单位是结核分枝杆菌抗原。此外，本发明涉及包含与BCG同时给予的本发明的融合多肽序列或核酸序列的疫苗的用途，所述疫苗或者与BCG混合或者分别在不同的位置或者途径中给药以制备所述免疫原性组合物，疫苗或药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式